capsaicin transdermal (Rx, OTC)

Brand and Other Names:Qutenza, Salonpas Gel Patch
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

transdermal patch (Rx, Qutenza)

  • 8%; contains 640mcg/sq.cm (179mg/patch)

transdermal patch (OTC, Salonpas Gel Patch)

  • 0.025%
  • 0.075%

Neuropathic Pain

Qutenza is indicated for neuropathic pain associated wtih postherpetic neuralgia

Qutenza (Rx): Single 60-minute application of up to 4 patches to dry, intact (unbroken) skin

May repeat no more frequently than q3Months

Skeletomuscular Pain

Salonpas Gel Patch (OTC): Apply patch to affected area up to 3-4 times daily for 7 days; patch may remain in place for up to 8 hr

Safety and efficacy not established

Next:

Adverse Effects

>10%

Quetenza transdermal patch

Transient increased pain at application site (63%)

Application site erythema (42%)

1-10%

Quetenza transdermal patch

Nausea (5%)

Vomiting (3%)

Pruritus at application site (2%)

Papules at application site (6%)

Skin dryness at application site (2%)

<1%

Quetenza transdermal patch

Exfoliation

Dizziness

Cough

Skin odor

Headache

Dysguesia

Previous
Next:

Warnings

Contraindications

Hypersensitivity

Cautions

Monitor for at least 1 hour after patch application because of risk for increased blood pressure

Do not apply to face or scalp to avoid exposure to eyes or mucous membranes

Remove patch gently to avoid aerosolization (airborne capsaicin can result in coughing or sneezing)

Treated area may be sensitive to heat for several days (eg, hot water, direct sunlight, vigorous exercise)

Use caution in patients with uncontrolled hypertension, history of cerebrovascular events

Previous
Next:

Pregnancy & Lactation

Pregnancy Category: B

Lactation: Not known whether distributed in breast milk, do not nurse

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Transient receptor potential vanilloid-1 (TRPV1) agonist; topical application causes initial TRPV1 stimulation that may cause pain, followed by pain relief by reduction in TRPV1-expressing nociceptive nerve endings

Pharmacokinetics

Absorption: systemic absorption negligible

Peak plasma concentration: Transient, low (<5 ng/mL) systemic exposure in one-third of patients following 60-min application; 4.6 ng/mL was highest level detected

Half-life: 1.64 hr

Previous
Next:

Administration

Transdermal Administration

Application preparation (Quetenza)

  • Use nitrile gloves during application process, latex gloves do not provide adequate protection
  • Clipping hair (do not shave) if necessary
  • Gently wash treatment area with mild soap and water, dry thoroughly
  • Patch may be cut to match size and shape of treatment area (cut to size/shape before removing protective release liner)
  • Pretreat area with topical anesthetic to reduce pain associated with patch application
  • Apply patch within 2 hours of opening package

Patch removal (Qutenza)

  • Gently remove and slowly roll them inward (avoid aerosolization)
  • Cleanse skin by generously applying cleansing gel (supplied with patch) to affected area, leave on for at least 1 minute, then remove with dry wipe and gently wash area with mild soap and water
Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.